Name | Title | Contact Details |
---|
IQVIA is a leading global provider of information, innovative technology solutions and contract research services focused on using data and science to help healthcare clients find better solutions for their patients. Formed through the merger of IMS Health and Quintiles, IQVIA offers a broad range of solutions that harness advances in healthcare information, technology, analytics and human ingenuity to drive healthcare forward. IQVIA enables companies to rethink approaches to clinical development and commercialization, innovate with confidence as well as accelerate meaningful healthcare outcomes. IQVIA has approximately 55,000 employees in more than 100 countries, all committed to making the potential of human data science a reality. IQVIAs approach to human data science is powered by the IQVIA CORE™, driving unique actionable insights at the intersection of big data, transformative technology and analytics with extensive domain expertise.
Conkerexe Biosciences is a Tempe, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Daily Cardinal Alumni Association is a Oak Park, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.
Horizon Blue Cross Blue Shield of New Jersey, the only licensed Blue Cross and Blue Shield plan in New Jersey, provides health insurance coverage to more than 3.6 million people throughout all of North, Central, and South Jersey. Horizon Blue Cross Blue Shield of New Jersey is best known for our managed care and traditional indemnity plans for individuals and employers — the cornerstone of our health care business. Horizon BCBSNJ traces its history back to 1932 when Associated Hospitals of Essex County, Inc. was formed as a multi-hospital prepayment plan. The company later became the nation`s first Blue Cross Plan. Horizon Blue Cross Blue Shield of New Jersey, is a not-for-profit, health service corporation. A 15-member Board of Directors governs the company for its members. There are no shareholders.